BBCMF (Lir Life Sciences) ROC (Joel Greenblatt) %: -42,061.54% (As of Jan. 2026)


BBCMF Lir Life Sciences Corp BBCMF
15 GF Score
Price $0.05
View Full Analysis

What is Lir Life Sciences ROC (Joel Greenblatt) %?

Lir Life Sciences BBCMF -80.00% 15 ROC (Joel Greenblatt) % is -42,061.54% as of Jan. 2026. GuruFocus rates BBCMF with a GF Score™ of 15/100. Among 1,326 Biotechnology companies, Lir Life Sciences ranks worse than 93.14% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Lir Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2026 was -42,061.54%.

The historical rank and industry rank for Lir Life Sciences's ROC (Joel Greenblatt) % or its related term are showing as below:

BBCMF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -13564.71   Med: 0   Max: 0
Current: -13564.71

BBCMF's ROC (Joel Greenblatt) % is ranked worse than
93.14% of 1326 companies
in the Biotechnology industry
Industry Median: -297.95 vs BBCMF: -13564.71

Lir Life Sciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Lir Life Sciences  (OTCPK:BBCMF) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Lir Life Sciences ROC (Joel Greenblatt) % Related Terms


Lir Life Sciences ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Lir Life Sciences's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lir Life Sciences ROC (Joel Greenblatt) % Chart

Lir Life Sciences Annual Data
Trend Apr24 Apr25
ROC (Joel Greenblatt) %
0.00 0.00

Lir Life Sciences Quarterly Data
Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial 0.00 0.00 0.00 -1,415.38 -42,061.54

BBCMF vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Lir Life Sciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lir Life Sciences ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lir Life Sciences's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Lir Life Sciences's ROC (Joel Greenblatt) % falls into.


BBCMF
15GF Score
Lir Life Sciences Corp BBCMF
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lir Life Sciences ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Oct. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.034 + 0 + 0.018) - (0.039 + 0 + 0)
=0.013

Working Capital(Q: Jan. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.051) - (0.057 + 0 + 0)
=-0.0060000000000001

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Lir Life Sciences for the quarter that ended in Jan. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Jan. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Oct. 2025  Q: Jan. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-5.468/( ( (0 + max(0.013, 0)) + (0 + max(-0.0060000000000001, 0)) )/ 1 )
=-5.468/( ( 0.013 + 0 )/ 1 )
=-5.468/0.013
=-42,061.54 %

Note: The EBIT data used here is four times the quarterly (Jan. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -42,061.54% mean?
Lir Life Sciences (BBCMF) has a ROC (Joel Greenblatt) % of -42,061.54% as of Jan. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Lir Life Sciences and its competitors. According to the industry distribution chart, Lir Life Sciences ranks #1235 out of 1326 companies in the Biotechnology industry, placing it in the top 93.1%.
Is Lir Life Sciences' ROC (Joel Greenblatt) % too high?
Lir Life Sciences' current ROC (Joel Greenblatt) % is -42,061.54%. Based on the distribution chart, Lir Life Sciences ranks #1235 out of 1326 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lir Life Sciences has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lir Life Sciences ranks #1235 out of 1326 companies for ROC (Joel Greenblatt) %. This places Lir Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Lir Life Sciences and its competitors. Lir Life Sciences's current ROC (Joel Greenblatt) % is -42,061.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (BBCMF) has a current ROC (Joel Greenblatt) % of -42,061.54%. The current ROC (Joel Greenblatt) % is -42,061.54%. Lir Life Sciences' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Lir Life Sciences (BBCMF), the current ROC (Joel Greenblatt) % is -42,061.54% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lir Life Sciences Business Description

Other Exchanges N790:GermanySKNY:Canada
Address 505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
15GF Score

Get the complete analysis for BBCMF

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.05
Price